Klebsiella Cluster Endophthalmitis following Intravitreal Bevacizumab : Role of Early Detection, Pars Plana Vitrectomy, and Intracameral Moxifloxacin

AIM: To report the clinical profile, outcomes of early vitrectomy for cluster endophthalmitis developing after intravitreal Bevacizumab (IVB), and discuss the role of prophylactic intracameral moxifloxacin for eyes undergoing combined cataract surgery with IVB.

METHODS: Single center, retrospective analysis of 35 consecutive eyes developing post-IVB inflammation.

RESULTS: Of the 35 eyes that were administered IVB (27 eyes 'IVB alone' and 8 eyes 'IVB with cataract surgery'). Endophthalmitis developed in 28 eyes, 6 eyes were managed with Intravitreal antibiotic (IVAB) alone, while 22 eyes required early vitrectomy. Only one eye undergoing a combined phacoemulsification with IVB developed endophthalmitis. Majority(26/28) of the eyes achieved visual acuity equal to/greater than pre-IVB injection vision over a period of 3.15 ± 3.2 months.

CONCLUSION: Early detection and prompt PPV were effectual for achieving good functional outcomes in our cluster of post-IVB Klebsiella endophthalmitis. Intracameral moxifloxacin was protective in cases undergoing combined cataract surgery with IVB.

Errataetall:

CommentIn: Ocul Immunol Inflamm. 2022 Jan 2;30(1):2-4. - PMID 35286229

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:30

Enthalten in:

Ocular immunology and inflammation - 30(2022), 1 vom: 02. Jan., Seite 11-15

Sprache:

Englisch

Beteiligte Personen:

Kohli, Gaurav Mohan [VerfasserIn]
Shenoy, Pratik [VerfasserIn]
Malhotra, Pawan Puneet [VerfasserIn]
Tripathi, Shubhi [VerfasserIn]
Shetty, Sachin [VerfasserIn]
Sen, Alok [VerfasserIn]

Links:

Volltext

Themen:

2S9ZZM9Q9V
Anti-Bacterial Agents
Bevacizumab
Journal Article
Moxifloxacin
U188XYD42P
Vitrectomy in Klebsiella cluster endophthalmitis

Anmerkungen:

Date Completed 16.03.2022

Date Revised 22.04.2022

published: Print-Electronic

CommentIn: Ocul Immunol Inflamm. 2022 Jan 2;30(1):2-4. - PMID 35286229

Citation Status MEDLINE

doi:

10.1080/09273948.2020.1808229

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM315363037